Acinetobacter spp. are associated with a higher mortality in intensive care patients with bacteremia: A survival analysis

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Leão, Aline C Q ^a   Menezes, Paulo R ^a   Oliveira, Maura S ^a   Levin, Anna S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acinetobacter; Bacteremia; Intensive care units; Prognosis; Survival analysis

Indexed keywords

ACINETOBACTER; ADOLESCENT; ADULT; AGED; APACHE; ARTICLE; BACTEREMIA; BRAZIL; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DISEASE SEVERITY; ENTEROBACTER; ENTEROCOCCUS; FEMALE; HUMAN; INTENSIVE CARE; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; ACINETOBACTER INFECTIONS; COMORBIDITY; CRITICAL ILLNESS; EPIDEMIOLOGY; INTENSIVE CARE UNIT; KLEBSIELLA INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BRAZIL; COMORBIDITY; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; MALE; MIDDLE AGED; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84992489316     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1695-8     Document Type: Article

References (30)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538-82.
2. Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, et al. The significance of Acinetobacter baumannii bacteremia compared with Klebsiella pneumonia bacteremia: risk factors and outcomes. J Hosp Infect. 2006;64:282-7.
3. Marra AR, Camargo LF, Pignatari AC, Sukiennik T, Behar PR, Medeiros EA, et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. J Clin Microbiol. 2011;49:1866-71.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-17.
5. Jerassy Z, Yinnon AM, Mazouz-Cohen S, Benenson S, Schlesinger Y, Rudensky B, et al. Prospective hospital-wide studies of 505 patients with nosocomial bacteremia in 1997 and 2002. J Hosp Infect. 2006;62:230-6.
6. Eberle BM, Schnüriger B, Putty B, Bamparas G, Kobayashi L, Inaba K, et al. The impact of Acinetobacter baumannii infections on outcome in trauma patients: a matched cohort study. Crit Care Med. 2010;38:2133-8.
7. Tonacio AC, Oliveira MS, Malbouisson LM, Levin AS. Trauma is associated with a better prognosis in intensive care patients with Acinetobacter infections. Infection. 2014;42:89-95.
8. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197:1079-81.
9. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad Bugs, No Drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1-12.
10. Jung JY, Park MS, Kim SE, Park BH, Son JY, Kim EY, et al. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis. 2010;10:228.
11. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-32.
12. Rhee JY, Kwon KT, Ki HK, Shin SY, Jung DS, Chung DR, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock. 2009;31:146-50.
13. Zimmerman JE, Knaus WA, Sun X, Wagner DP. Severity stratification and outcome prediction for multisystem organ failure and dysfunction. World J Surg. 1996;20:401-5.
14. Murray SB, Bates DW, Long Ngo MS, Ufberg JW, Shapiro NI. Charlson Index is associated with one-year mortality in emergency department patients with suspected infection. Acad Emerg Med. 2006;13:530-6.
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. Wayne: CLSI; 2010. Document No. M100-S20.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. Wayne: CLSI; 2011. Document No. M100-S21.
17. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl Med. 2010;362:1804-13.
18. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey JW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010;54:3717-22.
19. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8:751-62.
20. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34:1589-96.
21. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteremia receiving appropriate and inappropriate empirical therapy. J Antimicro Chemother. 2006;57:1251-4.
22. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteremia. J Antimicrob Chemother. 2007;59:525-30.
23. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med. 2003;31:2478-82.
24. Kaul R, Burt JA, Cork L, Dedier H, Garcia M, Kennedy C, et al. Investigation of a multiyear multiple critical care unit outbreak due to relatively drugsensitive Acinetobacter baumannii: risk factors and attributable mortality. J Infect Dis. 1996;174:1279-87.
25. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect. 2003;9:412-8.
26. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med. 2003;29:471-5.
27. Park KH, Shin JH, Lee SY, Kim SH, Jang MO, Kang SJ, et al. The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies. PLoS One. 2013;8:e65026.
28. Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis. 2011;52:352-60.
29. Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect. 2012;64:282-90.
30. Peleg AY, de Breiji A, Adams MD, Cerqueira GM, Mocali S, Galardini M, et al. The success of Acinetobacter species: genetic, metabolic and virulence attributes. PLoS One. 2012;7:e46984.